# Mygene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mygene

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.maijinggene.com
- Latest round: Series C (Dec 29, 2022)
- Investors on record: 8

## About

Based in Guangzhou, China, and established in 2015, Mygene operates as a medical solution provider that offers tumor detection services for users through utilizing gene-sequencing technology, with a third-party medical testing laboratory in Guangzhou. In December 2019, it reached an IVD partnership agreement with Illumina. In April 2017, the Silicon Valley R&D Center was completed. The Chief Scientist Officer, Chunlin Wang, graduated from Stanford University.

The company's genetic testing services can be categorized into lung cancer, colorectal cancer, breast cancer, gastrointestinal mesenchymal tumor, parenchymal tumor, childhood tumor, and prostate cancer.

## Funding rounds

- Series C, Dec 29, 2022 — Efung Capital, Jiuyo Capital, Shenzhen Jiesheng Yinfang Asset Management, Benchi Capital
- Series B, Dec 29, 2019 — CASH Capital, Greatwall Fund, Shenzhen Capital Real Estate Fund, Zhanglong Sanjun Venture Capital
- Series A, Apr 26, 2018 — Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A, Series B
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series B
- Greatwall Fund (https://capitalatlas.ai/funds/greatwall-fund) — Series B
- Zhanglong Sanjun Venture Capital (https://capitalatlas.ai/funds/zhanglong-sanjun-venture-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series C
- Shenzhen Jiesheng Yinfang Asset Management — Series C
- Benchi Capital (https://capitalatlas.ai/funds/benchi-capital) — Series C